Reflecting on 2025: A Year of Transformation for CytoDyn
As we usher in 2026, it’s crucial to look back and reflect on the progress CytoDyn made in the preceding year. The steadfast support from our shareholders has been vital in driving our mission forward. In 2025, we witnessed remarkable breakthroughs in our oncology research, particularly regarding the potential of our treatment, leronlimab, for solid tumors.
This past year marked a significant turning point for the Company, as we shared groundbreaking survival data from clinical studies involving metastatic Triple-Negative Breast Cancer (mTNBC). The revelations about increased survival rates for patients treated with leronlimab set a new standard for hope in cancer treatment. These promising results indicated that a combination of leronlimab with immune checkpoint inhibitors (ICIs) may pave the way for a revolutionary treatment paradigm in oncology.
Key Developments in Clinical Research
A notable highlight from 2025 was our analysis of long-term survivors who benefited from leronlimab. We discovered a consistent theme: successful outcomes hinged on three factors—treatment with leronlimab, a rise in PD-L1 levels on circulating tumor cells, and subsequent treatment with an immune checkpoint inhibitor. These findings suggest that leronlimab could effectively convert immune-resistant tumors into responsive ones, unlocking new possibilities for patient care.
Operational Achievements and Strategic Advancement
Throughout the year, our team worked diligently to enhance operational efficiency. Regulatory preparations were prioritized, ensuring our clinical strategies could meet evolving demands. We improved our internal processes to ensure data integrity and strengthened our relationships with various stakeholders, including regulators and investigators.
Financial Management and Sustainability
Our approach to financial stewardship in 2025 demonstrates our commitment to extending our operational runway. By focusing on cost management and channeling resources toward the most promising research avenues, we positioned CytoDyn for a sustainable future. This discipline in finance underpins our optimistic outlook as we move into 2026.
Setting the Stage for 2026
Looking ahead, the year 2026 promises to be pivotal. CytoDyn stands at the brink of critical clinical milestones that can redefine our role in the biotech landscape. Our ongoing trials in mTNBC and colorectal cancer are key initiatives aimed at confirming the mechanisms of action we’ve proposed.
As we prepare for the next phase of development, we anticipate significant data readouts that will further substantiate our clinical theories. Our ongoing discussions with regulatory officials are also expected to unlock potential new pathways that could enhance our clinical offerings. Building connections with key opinion leaders and institutions is also a priority as we aim to expand our collaborative efforts.
Anticipated Clinical Execution in 2026
We believe that 2026 can be the year CytoDyn firmly re-establishes itself as a leader in the biotechnology sector. The anticipated advancements in clinical execution and scientific validation are vital. With rigorous evaluation and commitment to data-driven outcomes, we are excited about what lies ahead.
Transformative Relationships and Collaborations
Collaboration is another cornerstone of our strategy moving into 2026. We are already in talks with various academic institutions to explore innovative treatments across different medical fields. For instance, one study aims to investigate the effects of leronlimab on patients with recurrent glioblastoma, highlighting our commitment to tackling formidable treatment challenges across oncology.
Final Reflections and Forward Momentum
In closing, I extend my deepest appreciation to all our shareholders for their enduring trust and belief in CytoDyn’s mission. As we embark on what promises to be our most pivotal year, we aim to leverage our accomplishments in 2025 and, with renewed vigor, tackle the challenges ahead. Working diligently and passionately, we intend to deliver substantial benefits to patients and continue advancing our groundbreaking treatments.
Wishing everyone a joyful and prosperous new year,
Jacob Lalezari, MD
CEO
Frequently Asked Questions
What were the key achievements of CytoDyn in 2025?
CytoDyn marked 2025 with notable advancements in clinical research, specifically related to the effects of leronlimab in treating metastatic Triple-Negative Breast Cancer.
How is CytoDyn preparing for 2026?
The company is focused on expanding clinical studies, refining regulatory pathways, and establishing collaborations with key institutions and researchers.
What impact could leronlimab have on cancer treatment?
Leronlimab’s potential to convert immune-resistant tumors to responsive ones may revolutionize treatment approaches in oncology, providing new hope for patients.
What role do financial management practices play for CytoDyn?
Prudent financial management helps CytoDyn extend its operational capabilities and direct resources toward promising therapeutic avenues, ensuring sustainability for future projects.
How does CytoDyn foster collaborations in 2026?
By engaging actively with academic centers and researchers, CytoDyn aims to foster innovative research collaborations that broaden the scope of inquiry in oncology and other fields.
